New Study Links Rare Gut Bacterium to Chronic Disease Prevention

The Discovery of CAG-170: A New Microbial Marker for Health

A groundbreaking study led by Alexandre Almeida has uncovered a previously unknown gut bacterium, named CAG-170, which appears in higher quantities in healthy individuals compared to those with 13 noncommunicable diseases. This discovery was made through a meta-analysis of 11,115 gut metagenomes from 39 countries. Published in Cell Host and Microbe, the research suggests that this microbe might serve as a universal indicator of health, regardless of geographic or dietary differences.

The significance of this finding lies in the fact that most microbiome studies focus on bacteria that can be easily cultured in laboratories. However, CAG-170 belongs to a group of microbes that resist standard culture techniques, making it difficult to study using traditional methods. The only reason researchers were able to identify it is due to the Unified Human Gastrointestinal genome catalogue (UHGG), which contains over 204,000 genomes assembled directly from sequencing data rather than from cultured isolates.

This technical detail has major implications. If a microbe consistently linked to disease-free status has been overlooked because it cannot be grown in a petri dish, then the field’s understanding of what constitutes a “healthy” gut may be incomplete. The association between CAG-170 and health was consistent across populations from 39 countries, suggesting that some microbial features of health may be universal.

The Challenge of Association vs. Causation

Despite the promising findings, the study does not establish a causal relationship between CAG-170 and health. It compared healthy individuals with those already diagnosed with chronic conditions but did not follow participants over time to see if those with higher levels of CAG-170 remained healthier. A more rigorous test would involve measuring CAG-170 abundance at baseline in an independent cohort and tracking whether these individuals develop fewer noncommunicable diseases over five years, even after accounting for other factors like diet, exercise, and smoking.

No such longitudinal dataset has been published yet, so CAG-170 is currently best viewed as a potential marker rather than a proven protective agent.

How 11,115 Metagenomes Revealed CAG-170

The study took a unique approach by pooling shotgun metagenomic sequences from existing datasets worldwide instead of recruiting its own participants. Each metagenome provides a snapshot of all microbial DNA present in a stool sample, capturing bacteria, archaea, and other organisms without the need for culturing them first.

By mapping these sequences against the UHGG reference catalogue, the researchers were able to identify fragments belonging to CAG-170, even though no one has isolated it in the lab. This method allows scientists to infer the presence and abundance of CAG-170 based on matching genomic data.

The results showed that CAG-170 was consistently more abundant in healthy individuals across different regions and study designs. The large-scale nature of the dataset gives the findings more weight than a single-population study, although it cannot eliminate all confounding variables.

Gaps Between Correlation and Clinical Application

Several challenges remain before CAG-170 can be used as a clinical tool. First, the definition of “healthy” versus “diseased” varied across the datasets, which could introduce noise into the comparison. Second, the statistical thresholds that identified CAG-170 as the top health-associated microbe have not been independently verified, raising questions about the robustness of the findings. Third, the inability to culture CAG-170 limits the ability to study its functions and potential therapeutic applications.

Without the ability to grow it in controlled conditions, researchers cannot easily test what it does in the gut, what metabolites it produces, or whether introducing it into a dysbiotic microbiome would improve health outcomes. Functional annotations from its genome sequence remain largely within bioinformatics platforms and have not yet translated into clear mechanistic hypotheses.

The Future of a “Health Signature”

Even if CAG-170 never becomes a standalone therapeutic, the concept of a microbial “signature of health” could change how clinicians assess chronic disease risk. Future screening tools might measure a panel of beneficial microbes, with CAG-170 as one component. A low score on such a panel could flag individuals whose microbiomes appear fragile or depleted.

For this vision to become reality, researchers must demonstrate that CAG-170 adds predictive value beyond simpler measures like overall microbial diversity. They also need to test whether lifestyle interventions—such as dietary fiber, fermented foods, and reduced antibiotic use—can reliably increase CAG-170 levels and correlate with better health outcomes.

At present, the meta-analysis does not address these intervention questions. For now, CAG-170 serves as a signpost, pointing to a vast, unexplored portion of the gut microbiome that traditional methods have missed. Its discovery highlights the importance of embracing the full diversity of the microbiome, as revealed by metagenomics, to better understand chronic disease.